![Egetis Therapeutics, Audiocast with teleconference, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ccae4327-1104-4f97-af74-b63e21b9bd83.png)
Egetis Therapeutics
4.635 SEK -2.01%Be the first to follow this company
Egetis Therapeutics is a drug development company, focused on projects in late clinical development in the field of orphan drugs for the treatment of serious and rare diseases with significant medical needs. Examples of the company's drug candidates are Emcitate, which is developed for patients with MCT8 deficiency, and Aladote, which is developed to reduce acute liver damage.
Revenue
57.6M
EBIT %
-563.89 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
EGTX
Daily low / high price
4.61 / 4.88
SEK
Market cap
1.36B SEK
Turnover
1.46M SEK
Volume
309K
Latest videos
Financial calendar
Interim report
2024-08-22
Interim report
2024-11-08
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Frazier Life Sciences | 13.2 % | 13.2 % |
Peder Walberg | 11.5 % | 11.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
![Egetis Therapeutics, Audiocast with teleconference, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ccae4327-1104-4f97-af74-b63e21b9bd83.png)
Egetis rapporterar topline-resultat från fas 2 studien Triac Trial II med Emcitate® (tiratricol) för behandling av MCT8-brist
Egetis announces topline results of the Phase 2 Triac Trial II with Emcitate® (tiratricol) for MCT8 deficiency
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools